Corporate Banner
Satellite Banner
Biomolecular Screening
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

The University of Paris Selects ACD/Percepta Software to Enhance Teaching and Research into Pharmaceuticals

Published: Monday, December 16, 2013
Last Updated: Monday, December 16, 2013
Bookmark and Share
ADME/Tox and PhysChem predictions on the Percepta Platform will help educate and train the next generation of pharmaceutical scientists.

The Université Paris-Sud, School of Pharmacy, has selected ACD/Labs’ ADME, Toxicity, and PhysChem predictors on the ACD/Percepta Platform, to enable in silico evaluation of pharmaceutical substances and research compounds.

The software is to be applied by undergraduate students to help them understand the effect of drugs on the body in terms of toxicity, and the body’s ability to use and dispose of a drug, i.e., ADME properties (absorption, distribution, metabolism, and excretion). Graduate students will use the software in their investigations towards innovative therapeutics from natural products. 

“As an educator I want to prepare my students for a successful career in the pharmaceutical industry. Software is used more and more, and our students will benefit from being exposed to these tools early in their education”, says Prof. Delphine Joseph. “Ease of use was very important to us, particularly since undergraduate classes will only use the software for one academic session, to understand the concepts behind drug design. Our research programs will benefit because graduate students will be able to profile synthetic modifications to molecular structures in silico, and investigate the effect on physiological behavior.”

Percepta modules provide predictions for oral bioavailability, CYP450 inhibition, blood brain barrier permeation, hERG inhibition, lipophilicity, and many other physiologically relevant properties. The values and supporting information provided in the software (such as similar structures, effect of pH, and color coded mapping) can help scientists understand the behavior of molecular structures, and direct discovery research in terms of achieving an optimal drug-like profile.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,200+ scientific posters on ePosters
  • More than 4,800+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
Liquid Biopsies: Miracle Diagnostic or Next New Fad?
Thanks to the development of highly specific gene-amplification and sequencing technologies liquid biopsies access more biomarkers relevant to more cancers than ever before.
Drug Candidates Reduce Abnormal Protein Production
New drug candidates improve cell ability to catch miss-folded proteins that could cause deadly diseases.
Supercomputing and Drug Discovery
New biotech company uses supercomputer simulations to speed up drug discovery and biotech molecule development.
Preventing Breast Cancer with Hops
Study of hops extract suggests prevention of breast cancer through chemical pathway activation.
Treatment Advancement for Gaucher and Parkinson's Diseases
NIH scientists identify molecule that may act as a possible treatment of neurological diseases.
Biomunex Confirms Optimal Properties and Activity of BiXAb® Antibodies
Biomunex‘s Plug-and-Play bispecific antibodies demonstrated excellent in vitro properties and in vivo activity positively differentiating their BiXAb platform from competing formats.
Liquid Biopsy Predicts Colon Cancer Recurrence
Scientists have used a genetic test that spots bits of cancer-related DNA circulating in the blood to accurately predict the likelihood of the disease’s return in some — but not all — of a small group of patients with early-stage colon cancer.
New Treatment for Rare Blood Cancers
Drug called midostaurin showed promise in an international clinical trial led by a Stanford physician.
Biomarker for Parkinson's Disease Found in Urine Samples
Protein identified as Parkinson's biomarker sourced from patient's stored frozen urine samples.
Testing for Malaria or Cancer at Home
Chemist develops tech to save lives in rural Africa.
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,200+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,800+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!